DRUG · Unmapped registry intervention
LDE225
Find medicine records ·
Find other trials using this name
Clinical trial
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
NCT01576666
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
BKM120
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedPhase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Dose Escalationunresolved
Safetyunresolved
Preliminary Efficacyunresolved
Advanced Solid Tumorsunresolved
Metastatic Breast Cancerunresolved
Advanced Pancreatic Adenocarcinomaunresolved
Metastatic Colorectal Cancerunresolved
Recurrent Glioblastoma Multiformeunresolved
Gastric Cancerverified · MONDO: gastric cancer
Gastroesophageal Junction Cancerunresolved
Triple Negative Metastatic Breast Cancerunresolved
Interventions
Sponsors & collaborators
Novartis Pharmaceuticalslead sponsor
Mapped research locations
DallasTexas, United States2BarcelonaCatalonia, Spain2HoustonTexas, United States1BostonMassachusetts, United States1Los AngelesCalifornia, United States1PhiladelphiaPennsylvania, United States1San FranciscoCalifornia, United States1TampaFlorida, United States1PortlandOregon, United States1DurhamNorth Carolina, United States1Salt Lake CityUtah, United States1RochesterMinnesota, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01576666 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.